Photocure aktie (PHO) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Stenocare genomför nu en emission – investera i medicinsk cannabis (annons)

Pressmeddelanden från Photocure

 Bevaka pressreleaser
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Photocure ASA: Transactions made under share buyback program

Oslo, 5 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 Decemb...

Cision • 05 Jan 08:47

Photocure ASA - Share option grant

Oslo, Norway, 23 December - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Cision • 23 Dec 2024 08:02

Photocure ASA: Initiation of a share buyback

Oslo, Norway, 19 December 2024: The Company has decided to initiate a buyback of up to 300,000 of its own shares for a total maximum amount ...

Cision • 19 Dec 2024 08:02

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 3 December 2024: Board member Ghizlane Tagmouti has on 3 December 2024 acquired 4,782 shares at a price per share of NOK 50.

Cision • 03 Dec 2024 15:14

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 3 December 2024: Board member Ghizlane Tagmouti has on 2 December 2024 acquired 20,218 shares at an average price of NOK 50.

Cision • 03 Dec 2024 07:00

Photocure ASA: Results for the third quarter of 2024

Oslo, Norway, 13 November 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 120.

Cision • 13 Nov 2024 08:00

Photocure ASA: Invitation to presentation of third quarter 2024 financial results

Oslo, Norway, 6 November 2024: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2024 financial results on Wednesday 13 No...

Cision • 06 Nov 2024 16:48

Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China

Oslo, Norway, November 5, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SS...

Cision • 05 Nov 2024 10:34

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Press Release – Oslo, Norway, September 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...

Cision • 30 Sep 2024 08:00

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Press Release – Oslo, Norway, September 27, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an ag...

Cision • 27 Sep 2024 08:00

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

Press Release – Oslo, Norway, September 17, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...

Cision • 17 Sep 2024 12:09

Photocure ASA: Results for the second quarter of 2024

Oslo, Norway, 7 August 2024 - Photocure ASA (OSE:PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.

Cision • 07 Aug 2024 08:00

Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results

Oslo, Norway, 31 July 2024: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2024 financial results ...

Cision • 31 Jul 2024 12:00

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Oslo, Norway, July 15, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agre...

Cision • 15 Jul 2024 17:52

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Press Release – Oslo, Norway, June 4, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced acti...

Cision • 04 Jun 2024 08:00

Photocure ASA – Annual general meeting held

Oslo, Norway, 23 May 2024: Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).

Cision • 23 May 2024 19:33

Photocure ASA: Results for the first quarter of 2024

Oslo, Norway, 15 May 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 116.

Cision • 15 May 2024 08:00

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Press Release – Oslo, Norway, May 12, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmac...

Cision • 12 May 2024 10:23

Photocure ASA: Invitation to presentation of first quarter 2024 financial results

Oslo, Norway, 8 May 2024: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2024 financial results on Wednesday 15 May 202...

Cision • 08 May 2024 22:36

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Press Release – Oslo, Norway, May 7, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress...

Cision • 07 May 2024 08:00

Photocure ASA – Notice of the Annual General Meeting 23 May 2024

Oslo, Norway, 30 April 2024: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 23 May 2024 at 17...

Cision • 30 Apr 2024 13:48

Photocure ASA: Annual Report 2023

Oslo, Norway, 30 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.

Cision • 30 Apr 2024 11:52

Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy

Press Release – Oslo, Norway, April 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the Ameri...

Cision • 30 Apr 2024 07:30

Photocure ASA – Share option grant

Oslo, Norway, 25 April 2024 – Photocure ASA (the "Company") (OSE: PHO) refers to its previous stock exchange announcement on 21 December 202...

Cision • 25 Apr 2024 21:53

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Press Release – Oslo, Norway, April 8, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congre...

Cision • 08 Apr 2024 12:32

Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference

OSLO, Norway, April 5, 2024 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Da...

Cision • 05 Apr 2024 07:30

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Press release – Oslo, Norway, March 28, 2024: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Racial Diff...

Cision • 28 Mar 2024 13:13

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Press Release – Oslo, Norway, March 18, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharm...

Cision • 18 Mar 2024 10:05

Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO

Press Release – Oslo, Norway, February 23, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...

Cision • 23 Feb 2024 08:34

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Press Release – Oslo, Norway, February 22, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...

Cision • 22 Feb 2024 08:37

Photocure ASA: Results for the fourth quarter of 2023

Oslo, Norway, 21 February 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 114.

Cision • 21 Feb 2024 08:00

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

Oslo, Norway, 19 February 2024: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2023 financia...

Cision • 19 Feb 2024 09:29

Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024

Oslo, Norway, January 29, 2024: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that its partner Asieris presented Phase III...

Cision • 29 Jan 2024 08:47

Photocure ASA – Share option grant

Oslo, Norway, 20 December 2023 - Photocure ASA (the "Company") (OSE: PHO) cancels up to 1,400,428 options and has subsequently re-issued 399...

Cision • 21 Dec 2023 08:00

SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy

Press release – Oslo, Norway, December 1, 2023: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that new evidence from routi...

Cision • 01 Dec 2023 07:30

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Press Release – Oslo, Norway, November 29, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...

Cision • 29 Nov 2023 10:05

Photocure to present at four investor conferences in November/December 2023

Press Release – Oslo, Norway, November 20, 2023: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four i...

Cision • 20 Nov 2023 17:50

Photocure ASA: Results for the third quarter of 2023

Oslo, Norway, 8 November 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 107.

Cision • 08 Nov 2023 08:00

Photocure ASA: Invitation to presentation of third quarter 2023 financial results

Oslo, Norway, 1 November 2023: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2023 financial results on Wednesday 8 Nov...

Cision • 01 Nov 2023 08:21

Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress

Press Release – Oslo, Norway, October 12, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pha...

Cision • 12 Oct 2023 10:32

Photocure Partner Asieris to present first results for its Hexvix Phase III clinical trial in China at the SIU 2023 Annual Meeting

Press Release – Oslo, Norway, October 7, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Phar...

Cision • 07 Oct 2023 08:00

New Health Economic analysis in France concludes there is insignificant cost difference between White Light and Blue Light Cystoscopy use when applying ccAFU guidelines

Press release – Oslo, Norway, October 6, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of “A cost-consequences ...

Cision • 06 Oct 2023 15:07

Photocure ASA: Change of Board Composition

Oslo, Norway, 28 September 2023: Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.

Cision • 27 Sep 2023 18:05

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Press Release – Oslo, Norway, September 20, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...

Cision • 20 Sep 2023 12:17

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 30 August 2023: Board member Dylan Hallerberg has on 29 August 2023 acquired 150,000 shares at an average price of NOK 43.

Cision • 30 Aug 2023 16:06

Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint

Press Release – Oslo, Norway, August 11, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Phar...

Cision • 11 Aug 2023 11:05

Photocure ASA: Results for the second quarter and first half of 2023

Oslo, Norway, 9 August 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 115.

Cision • 09 Aug 2023 08:00

Photocure ASA: Invitation to presentation of second quarter and first half year 2023 financial results

Oslo, Norway, 3 August 2023: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2023 financial results...

Cision • 03 Aug 2023 08:13

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

Press Release – Oslo, Norway, July 6, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmac...

Cision • 06 Jul 2023 10:39

Photocure ASA – Share option grant

Oslo, Norway, 24 May 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Cision • 24 May 2023 08:31

Photocure ASA: Results for the first quarter of 2023

Oslo, Norway, 10 May 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 105.

Cision • 10 May 2023 08:00

Photocure ASA – Correction: Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET).

Cision • 04 May 2023 13:22

Photocure ASA – Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET).

Cision • 03 May 2023 18:41

Photocure ASA: Invitation to presentation of first quarter 2023 financial results

Oslo, Norway, 3 May 2023: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2023 financial results on Wednesday 10 May 202...

Cision • 03 May 2023 11:38

Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light Cystoscopy

Press Release – Oslo, Norway, May 2, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that results from the Nordic Regi...

Cision • 02 May 2023 17:00

Photocure ASA – Notice of the Annual General Meeting 3 May 2023

Oslo, Norway, 12 April 2023: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 3 May 2023 at 17:...

Cision • 12 Apr 2023 16:01

Photocure ASA: Annual Report 2022

Oslo, Norway, 12 April 2023: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2022.

Cision • 12 Apr 2023 16:01

Photocure ASA – Share option grant

Oslo, Norway, 30 March 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Cision • 30 Mar 2023 10:48

Photocure provides update on Karl Storz’s commitment to maximize the commercial adoption of Saphira™ and decision to discontinue flexible BLC tower production in the U.S.

Oslo, Norway, March 21, 2023 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces Karl Storz’s continued commitment to blue lig...

Cision • 21 Mar 2023 21:57

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Oslo, Norway, March 14, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abs...

Cision • 14 Mar 2023 08:00

Photocure ASA: Results for the fourth quarter of 2022

Oslo, Norway, 23 February 2023 Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.

Cision • 23 Feb 2023 08:00

Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC

Press release – Oslo, Norway, February 20, 2023: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from...

Cision • 20 Feb 2023 07:30

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2022 financial results

Oslo, Norway, 16 February 2023: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2022 financia...

Cision • 16 Feb 2023 13:02

New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

Press release – Oslo, Norway, January 3, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Clinical a...

Cision • 03 Jan 2023 07:30

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

Press release – Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at th...

Cision • 05 Dec 2022 07:30

Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting

Oslo, Norway, November 7, 2022: Photocure ASA., (OSE: PHO), announces that The United States Centers for Medicare & Medicaid Services (CMS) ...

Cision • 07 Nov 2022 07:30

Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China

Press Release – Oslo, Norway, November 4, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pha...

Cision • 04 Nov 2022 10:36

Photocure ASA: Results for the third quarter of 2022

Oslo, Norway, 2 November 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 96.

Cision • 02 Nov 2022 08:00

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Oslo, Norway, 25 October 2022: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2022 financial results on Wednesday 2 Nov...

Cision • 25 Oct 2022 08:44

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

Press release – Oslo, Norway, October 4, 2022: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data and it...

Cision • 04 Oct 2022 07:30

Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

Karl Storz and Photocure to collaborate on commercializing the high-definition system Press Release – Oslo, Norway, September 28, 2022: Pho...

Cision • 28 Sep 2022 07:30

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

Press release – Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder Cancer Company, announces the publication of first results fr...

Cision • 20 Sep 2022 07:30

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Press release – Oslo, Norway, September 15, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris P...

Cision • 15 Sep 2022 09:35

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology

Press release – Oslo, Norway, September 8th, 2022: Photocure ASA, The Bladder Cancer Company, is delighted to continue supporting the global...

Cision • 08 Sep 2022 07:30

Photocure appoints Anders Neijber, MD, PhD as Chief Medical Officer, Global Medical Affairs and Clinical Development

Press Release – Oslo, Norway, September 1, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Dr...

Cision • 01 Sep 2022 07:30

Photocure ASA: Results for the second quarter of 2022

Oslo, Norway, 10 August 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 99.

Cision • 10 Aug 2022 08:00

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative d...

Cision • 09 Aug 2022 09:38

Photocure ASA: Invitation to presentation of second quarter and first half year 2022 financial results

Oslo, Norway, 4 August 2022: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2022 financial results...

Cision • 04 Aug 2022 15:02

Photocure Provides Update on Anticipated Commercial Availability of Karl Storz’s New Blue Light System in the United States

Oslo, Norway, July 27, 2022: Photocure ASA, The Bladder Cancer Company, announces that it has been informed by Karl Storz that the U.

Cision • 27 Jul 2022 14:16

Photocure Collaborations at EAU Support the Latest Advancements in Bladder Cancer Technology

High-definition blue light cystoscopic imaging showcased at the European Association of Urology (EAU) Congress, Amsterdam Press release - O...

Cision • 05 Jul 2022 07:30

Photocure ASA: Share capital increase registered

Oslo, Norway, 13 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 3 J...

Cision • 13 Jun 2022 08:10

Positive Data from the Danish National Patient Registry presented at the 2022 Nordic Urologisk Forening (NUF) Congress in Helsinki

Lower rates of bladder cancer recurrence and progression demonstrated in clinics with a high level of blue light cystoscopy (BLC[®]) use in ...

Cision • 13 Jun 2022 07:30

Photocure ASA: Exercise of employee share options

Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 Ju...

Cision • 03 Jun 2022 09:00

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 Ju...

Cision • 03 Jun 2022 08:46

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 1 June 2022: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 1 June 2022 exercised...

Cision • 01 Jun 2022 14:24

Photocure ASA - Initiation of a share buyback

Oslo, Norway, 1 June 2022: Photocure ASA ("Photocure" or the "Company") has decided to initiate a buyback of up to 36,000 of its own shares ...

Cision • 01 Jun 2022 14:14

Blue Light Cystoscopy continues to make news at AUA 2022

Press Release – Oslo, Norway, May 18, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the conclusion of a productive A...

Cision • 18 May 2022 07:30

Photocure ASA: Results for the first quarter of 2022

Oslo, Norway, 11 May 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 81.

Cision • 11 May 2022 08:00

Photocure ASA: Invitation to presentation of first quarter 2022 financial results

Oslo, Norway, 5 May 2022: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2022 financial results on Wednesday 11 May 202...

Cision • 05 May 2022 08:45

Photocure ASA – Annual general meeting held

Oslo, Norway, 28 April 2022: Photocure ASA (OSE: PHO), held its annual general meeting on 28 April 2022 at 17:00 hours (CET).

Cision • 28 Apr 2022 17:53

Photocure ASA: Final grant of conditional share options

Oslo, Norway, 26 April 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") (OSE: PHO) publ...

Cision • 26 Apr 2022 15:32

Photocure ASA – Notice of the annual general meeting 28 April 2022

Oslo, Norway, 7 April 2022: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Advokatfirmaet Selmer AS' pr...

Cision • 07 Apr 2022 13:05

Photocure ASA: Annual Report 2021

Oslo, Norway, 6 April 2022: Photocure ASA today announces the publication of the Annual Report 2021, included the ESG report for 2021.

Cision • 06 Apr 2022 20:50

Photocure to Participate in Two Investor Conferences in April: DNB Small & Medium Enterprises and Needham Healthcare

Press Release – Oslo, Norway, 29 March 2022, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Execut...

Cision • 29 Mar 2022 17:00

Photocure ASA: Share capital increase registered

Oslo, Norway, 16 March 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 14...

Cision • 16 Mar 2022 11:04

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 14 March 2022: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 14 March 2022 exerc...

Cision • 14 Mar 2022 13:01

Photocure Partner Asieris announces CDE Approval for Hexvix Clinical Real-World Evidence Study in China

Press release – Oslo, Norway, March 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharm...

Cision • 11 Mar 2022 08:39

Photocure announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Press release – Oslo, Norway, 4 March 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into an excl...

Cision • 04 Mar 2022 08:00

Photocure Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Press release – Oslo, Norway, 28 February 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of new resul...

Cision • 28 Feb 2022 07:30

Photocure ASA: Results for the fourth quarter of 2021

Oslo, Norway, 23 February 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.

Cision • 23 Feb 2022 07:30